Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma — Stella

Home/Osteosarcoma Recurrent/

View on ClinicalTrials.gov

Recruiting

Back to Osteosarcoma Recurrent trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Arthur M. Blank Children's Healthcare of Atlanta, Atlanta, Georgia

Key details

Phase

Early testing

Sponsor

Emory University

Collaborators

Iterion Therapeutics

Enrollment target

~24 participants

Started

January 2026

Primary completion

May 2028

Age range

1 Year – 30 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.